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Abstract
Background: Surgical hepatic resection remains the treatment of choice for patients with liver
metastases from colorectal cancer despite the use of alternative therapeutic strategies. Although
this procedure provides long-term survival in a significant number of patients, 50–75% of the
patients develop intra- and/or extrahepatic recurrence. One possible reason for tumor recurrence
may be intraoperative hematogenous tumor cell dissemination due to mechanical manipulation of
the tumor during hepatic resection. Surgical technique may have an influence on hematogenous
tumor cell spread. We hypothesize that hematogenous tumor cell dissemination may be reduced
by using the anterior approach technique compared to conventional liver resection.
Methods/Design: This is a multi-centre prospective randomized controlled, superiority trial to
compare two liver resection techniques of liver metastases from colorectal cancer. 150 patients
will be included and randomized intraoperatively after surgical exploration just prior to resection.
The primary objective is to compare the anterior approach with the conventional liver resection
technique with regard to intraoperative haematogenous tumor cell dissemination. As secondary
objectives we examine five year survival rates (OS and DFS), blood loss, duration of operation,
requirement of blood transfusions, morbidity rate, prognostic relevance of tumor cell detection in
blood and bone marrow and the comparison of tumor cell detection by different detection
methods.
Conclusion: This trial will answer the question whether there is an advantage for the anterior
approach technique compared to the conventional resection group with regard to tumor cell
dissemination. It will also add further information about prognostic differences, safety, advantages
and disadvantages of each technique.
Trial registration: Current controlled trials – ISRCTN45066244
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Background
Despite the use of alternative therapy strategies surgical
resection of colorectal liver metastases remains the treat-
ment of choice and is associated with long-term survival
in a significant number of patients [1,2]. After curative
resection of colorectal liver metastases the 5-year survival
rate ranges from 20% to 51% depending on preoperative
selection criteria and published series [3]. However, up to
75% of resected patients will develop extra- or intrahe-
patic tumor recurrence [4]. One possible cause for this
tumor recurrence may be intraoperative hematogenous
tumor cell dissemination due to mechanical manipula-
tion of the tumor during hepatic resection [5].
Recently, RT-PCR based protocols were developed for the
detection of disseminated tumor cells [6]. We developed
a sensitive and specific CK 20 RT-PCR system for detection
of disseminated colorectal cancer cells in blood, bone
marrow and lymph nodes [7-9]. By using the CK 20 RT-
PCR, we demonstrated that there is a significantly
enhanced intraoperative hematogenous tumor cell spread
during resection of primary tumor and liver metastases
from colorectal cancer [10,11]. In 12 of 38 patients
(31,6%) with colorectal liver metastases tumor cells were
detected only during or during and after surgery, possibly
indicating an intraoperative tumor cell dissemination [9].
Statistical analysis revealed an increased risk for intraoper-
ative tumor cell dissemination during major liver resec-
tion for metastases compared with minor liver resections
or resection of the primary tumor (Odds ratio = 3.07; p =
0.05). These observations are in accordance with the con-
cept of intraoperative tumor cell dissemination, because a
higher degree of intraoperative manipulation of the liver
and tumor in more extensive resections should result in a
higher incidence of tumor cell shedding. Recent follow up
of the patients with resection of colorectal liver metastases
has shown, that intraoperative detection of circulating
tumor cells is associated with a worse prognosis [10].
Surgical technique might influence hematogenous tumor
cell spread and patient's prognosis. Initially, Liu et al.
showed in a retrospective study of patients with hepato-
cellular carcinoma a significantly improved survival rate
for patients undergoing the anterior approach technique
(with primary dissection of the parenchyma and without
mobilization of the liver) compared to conventional liver
resection [12]. This study was followed by a prospective
randomized controlled study in which the use of the ante-
rior approach technique for liver resection in large hepa-
tocellular carcinomas was confirmed to have a
significantly better overall survival compared to the use of
the conventional technique[13].
The hypothesis of this study is that intraoperative hema-
togenous tumor cell dissemination could be reduced or
prevented by using the anterior approach technique in
resection of metastasis of colorectal cancer in the liver.
Methods/design
Aim of the study
The objective of this trial is to compare two different sur-
gical techniques for the resection of colorectal liver metas-
tases with regard to intraoperative hematogenous tumor
cell dissemination, survival (overall and disease-free sur-
vival), blood loss, duration of resection, transfusion
requirements, complications, relevance of tumor cell
detection in the bone marrow and comparison of differ-
ent tumor cell detection methods.
Trial population
The anterior approach trial includes patients with the clin-
ical diagnosis of metastatic colorectal cancer to the liver
who are being planned for elective and potentially cura-
tive (R0) resection of the right liver lobe. This study
includes patients over 18 years of age who are planned for
right hepatectomy (removal of segments 5–8), extended
right hepatectomy (removal of segments 5–8 and parts of
segment 4) or right trisegmentectomy (removal of seg-
ment 4–8). Based on the preoperative imaging the sur-
geon has to determine that the liver metastases can be
removed with both resection techniques. Patients with
extrahepatic disease, liver cirrhosis and tumor positive
lymph nodes in the hepatoduodenal ligament will be
excluded from the trial. A detailed overview of all eligibil-
ity criteria are given in Table 1.
Study design
The anterior approach trial is a registered
[ISRCTN45066244], prospective intraoperatively rand-
omized (expertise-based) multicenter trial of patients
who will undergo elective resection for colorectal liver
metastases. It is designed as a two-group parallel superior-
ity study. As the primary objective of this study is the
extent of intraoperative tumor cell dissemination we
hypothesize that intraoperative tumor cell shedding can
be reduced significantly in the anterior approach com-
pared to the conventional approach group.
Surgical Interventions
All surgical interventions in this trial follow standardised
described techniques which will be shortly described
below. A detailed description of all surgical techniques is
also in the study protocol.
Incision lines
Abdominal incision can be achieved according to the pref-
erence of the surgeon. A complete exploration of the
abdomen, including potential frozen sections (of suspi-
cious lesions or lymph nodes) is performed to decide
whether a curative resection is feasible. An intraoperativeBMC Surgery 2008, 8:6 http://www.biomedcentral.com/1471-2482/8/6
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ultrasound evaluation of the left liver is performed. If
both approaches seem possible for the surgeon randomi-
zation will be performed at this point.
Conventional approach
The liver will be mobilized from the retroperitoneum
including the division of short venous branches to the
inferior vena cava. In the next step the inflow control
(either intra- or extrahepatic) is performed by ligation and
division of right portal vein and hepatic artery. The out-
flow is controlled by ligation and division of the right
hepatic vein, and possibly, middle hepatic vein. Parenchy-
mal transection is performed according to surgeon's pref-
erence and local standards (e.g. stapler, Cusa, etc.).
Optionally, Pringle manoeuvre can be performed.
Anterior approach
Extrahepatic inflow control is maintained by ligation and
division of right portal vein and hepatic artery before any
mobilization of the right liver lobe. A hanging liver
manoeuvre is performed without manipulation of the
right lobe [14]. Afterwards, parenchymal transaction is
performed (with optional Pringle manoeuvre). This is fol-
lowed by the outflow control with ligation and division of
the right, and possibly, the middle hepatic vein. Finally,
the short venous branches of the inferior vena cava will be
divided and the liver will be mobilized out of the retroper-
itoneum.
Any deviation or change of the standardized operation
techniques will be regarded as a protocol violation. For
safety reasons, the operating surgeon is allowed to change
the surgical technique at any time point during the opera-
tion.
Sample acquisition
Blood sample: From each patient two central venous
blood samples will be obtained. One blood sample (10
cc) will be drawn after induction of general anesthesia
through a central venous catheter, which is routinely
placed just before surgery. Immediately after resection of
the liver metastases, 10 cc of central venous blood will
again be taken. The intraoperative blood sample will be
obtained without occlusion of the hepatoduodenal liga-
ment. If a wedge or segmental liver resection or other
organ resection is performed in addition to a right hepate-
ctomy the intraoperative blood sample will be obtained
after the right hepatectomy. Bone marrow sample: A bilat-
eral bone marrow sample (each 10 cc) will be taken after
induction of general anesthesia just prior to skin incision
after disinfection from both iliac crests. Bone marrow
sampling is optional for the patient.
Note: EDTA and not Heparin will be used as anticoagu-
lant for bone marrow and blood samples.
Sample size and statistical consideration
150 patients will be accrued to this study. Patients who
underwent R1 resection and patients with an intraopera-
tive blood loss of greater than 2000 cc will be excluded.
The sample size of this trial was calculated with regard to
the previous results and data from our study on hematog-
enous tumor cell dissemination during resection of liver
metastasis from colorectal cancer [10] and the study on
the use of the anterior approach as a new liver resection
technique in patients with hepatocellular carcinoma [12].
For statistical sample size calculation a 1:1 randomization
in both treatment groups was assumed.
Table 1: Eligibility Criteria
Inclusion criteria
(At study enrolment)
• Patients being considered for a potentially curative (R0) right hepatectomy (removal of segments 5,6,7,8), extended right hepatectomy 
(removal of segments 5,6,7,8, part of segment 4) or right trisegmentectomy (removal of segments 4,5,6,7,8) for colorectal liver metastases
• Age equal or greater than 18 years
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol, follow-
up schedules or from signing informed consent
• Written informed consent from each patient or the patient's legal guardian prior to entering the study
• No evidence of active or former concurrent malignant diseases (except non-melanous skin cancer)
Exclusion criteria
• Any extrahepatic disease, even if this will be resected concomitantly
• Liver cirrhosis
• Grossly positive lymph nodes in the hepatoduodenal ligament
• Positive margins after liver resection (R1) (Patients will be excluded from further follow up, the patient's data however will be recorded).
• Patients with an intraoperative blood loss of >= 2000 cc will be excluded from the analysis of tumor cell detection in blood samples but will be 
included in the rest of the analyses.BMC Surgery 2008, 8:6 http://www.biomedcentral.com/1471-2482/8/6
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From the analysis of the previous data we expect to detect
a difference of at least 30% in the proportion of intraop-
erative tumor cell dissemination between the two groups.
The incidence of hematogenous tumor cell dissemination
in the conventional group is reported to be 50–55% and
it will be expected to be 15–20% in the anterior resection
groups. To achieve a power of 90% (beta = 0.1) approxi-
mately 112 patients have to be recruited (two-sided test,
Type I error of 5%). Due to the expectation that about
25% of all the patients will have circulating tumor cells at
baseline we have to increase the total number of rand-
omized patients to 150 patients (75 in each arm). With
this sample size the study will have adequate power to
address the primary objective.
Randomisation, stratification and blinding
The study is conducted in a prospective randomized man-
ner. After giving informed consent and inclusion into the
study, patients will be randomized in the operating room
after surgical exploration just prior to resection by using
sealed opaque serial numbered envelopes. These enve-
lopes will be supplied by the Clinical Trials Centre (KSC)
of the Department of Surgery, University of Heidelberg.
The patients will be randomized 1:1 into each arm of the
two different liver resection techniques. As stratification
factors, the participating institution and the Fong score
will be used [15]. The Fong score predicts the risk of recur-
rence after surgical resection of colorectal metastases to
the liver. Two strata will be used (Fong score 0–2 and
3–5).
Endpoints
As primary endpoint, we choose the tumor cell detection
rate in blood samples obtained intraoperatively using a
CK 20 RT-PCR. The method is already established and this
was the endpoint for the sample size calculation and fur-
ther decision making. As secondary endpoints, overall
survival and disease-free survival will be recorded during
the follow-up in both groups. Further secondary end-
points are blood loss, duration time of resection, number
of blood products transfused, prognostic relevance of
tumor cell dissemination to the bone marrow, and post-
operative complications. All these parameters will be col-
lected prospectively as part of the study protocol.
Laboratory workup
The processing of blood and bone marrow samples will be
done in each participating institution using a standard
protocol. After processing, samples will be stored at -80°C
for further laboratory workup which will be centrally per-
formed at the Department of Surgery, University of Hei-
delberg. The samples from participating institutions will
be sent to the laboratory at the Department of Surgery,
University of Heidelberg by overnight service on dry ice.
The samples will be accompanied by positive controls to
ensure quality of processing and mailing of the samples.
Blood and bone marrow samples will be analyzed by a CK
20 RT-PCR as previously described [7].
RT-PCR
All PCR reactions will be accompanied by positive and
negative controls to ensure adequate performance of the
procedure. Two investigators independently judge the
results of the PCR. In case of different judgment (which in
case of RT-PCR virtually never happens), the PCR result
will be confirmed by hybridization.
The laboratory workup of all samples will be centrally per-
formed in the Department of Surgery, University of Hei-
delberg. The technician working up the sample and the
physician analyzing the test results are blinded for clinical
data of each patient
Clinical evaluation
The clinical evaluation of the patients includes a preoper-
ative, intraoperative and postoperative evaluation. In the
preoperative evaluation the operating surgeon has to eval-
uate whether the liver metastasis or metastases can be
resected by either technique. During the operation the
operating surgeon can change the technique at any time
during the procedure if necessary for the patients safety. In
this case the patient will be removed from the study.
Safety aspects and adverse advents
Both surgical techniques are well established procedures
and no specific side effects are expected in addition to the
known complications of liver resections. Furthermore, the
responsible surgeon can change the procedure at any
given time point during the operation.
All precautions will be used to minimize the potential
risks of bone marrow puncture which are bleeding,
hematoma and infection. Since the central venous cathe-
ter for blood sampling is routinely placed in the operating
theatre, no potential adverse effects of the blood sampling
are expected.
Adverse events will be recorded during the hospital stay
and the follow up.
Ethics and informed consent
The final protocol was approved by the ethics committee
of the University of Heidelberg. Written informed consent
is obtained from each patient in oral and written form
before inclusion in the study. The investigator will not
undertake any measures specifically required only for the
clinical trial until valid consent has been obtained. This
must be done in accordance with the national and local
regulatory requirements.BMC Surgery 2008, 8:6 http://www.biomedcentral.com/1471-2482/8/6
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Patients are informed about the strict confidentiality of
their personal data within this trial, but their medical
records may be reviewed for trial purposes by authorized
individuals other than their treating physician.
Patients will be informed about the additional specific
risk of a bone marrow aspiration, which is voluntarily and
will not lead to exclusion from the study in case of refusal.
It will be emphasized that the participation is voluntary
and that the patient is allowed to refuse further participa-
tion in the protocol whenever he/she wants. This will not
prejudice the patient's subsequent care.
The informed consent procedure is in accordance with the
ICH guidelines on Good Clinical Practice.
Follow up
The patients will undergo routine follow-up (physical
examination of the patients, tumor markers (CEA),
abdominal ultrasound and/or CT/MRI, chest X-ray, colon-
oscopy) at least once a year. Disease free survival and over-
all survival will be recorded; at each time point a follow-
up evaluation form will be completed.
As the prognostic impact of disseminated tumor cells is
still unclear, the clinical management and postoperative
treatment of the patients will not be influenced by the
results of this study. Decisions about further adjuvant
treatment (e.g. chemotherapy) of the patients are left to
the discretion of the treating oncologist.
Data management and quality assurance
This trial is coordinated by the Department of Surgery at
the University of Heidelberg. The data regarding tumor
cell detection in blood and bone marrow of all patients
will be entered in a password-protected database at the
Department of Surgery, University of Heidelberg. The
clinical data of all included patients will be centrally col-
lected in a database at the Department of Surgery, Univer-
sity of Heidelberg. To transfer the data to Heidelberg, the
evaluation forms will be sent from the participating cent-
ers via overnight service. The clinical and laboratory data
will be merged in the password-protected database at the
Department of Surgery, University of Heidelberg, Ger-
many.
All samples and clinical data will be tracked by means of
a unique research tracking number that will not be related
to any patient identifying information. The link between
research tracking numbers and patient identifiers will be
kept in a limited access database on a computer with pass-
word protection. Routine data quality reports will be gen-
erated to assess missing data and inconsistencies. Accrual
rates and accuracy of evaluations and follow-up will be
monitored periodically throughout the study period and
potential problems will be brought to the attention of the
study team for discussion and action. Random-sample
data quality and protocol compliance audits will be con-
ducted by the study team.
Only surgeons who performed 25 or more successful liver
resections are allowed to recruit patients for this study.
The records of the operations will be reviewed centrally in
order to identify protocol violations.
Analysis
We evaluate the influence of two different liver resection
techniques on the incidence of intraoperative hematoge-
nous tumor cell dissemination in patients with colorectal
liver metastases. Patients with circulating tumor cells
present in the bloodstream at baseline (before operation)
will be excluded from the primary analysis, hence the pri-
mary endpoint is the presence of disseminated tumor cells
after liver resection. Details of the timing of the different
blood samples drawn from each patient are provided.
The analyses will be performed as intention to treat anal-
yses.
An interim analysis regarding the incidence of intraopera-
tive tumor cell dissemination between the two arms in
this study will be undertaken after the randomization of
the first 75 patients. If the p-value is < 0.005, the study will
be terminated and it will be concluded that the anterior
approach technique significantly reduces intraoperative
tumor cell dissemination. If the p-value is > 0.65 the trial
will be terminated and it will be concluded that there is no
significant difference between the two techniques with
regard to intraoperative tumor cell dissemination. For a p-
value between 0.005 and 0.65, the study will be contin-
ued to the total number of 150 patients. The interim anal-
ysis is planned using the O'Brien-Fleming boundary with
a provision to stop early in favor of the null hypothesis.
Primary comparison of the proportion of patients with
disseminated tumor cells in the blood after liver resection
will be carried out by Fisher's exact test.
Secondary endpoints as blood loss and duration time of
resection will be evaluated by t-test, and amount of used
blood units and complication rates will be evaluated by
Fisher's exact test. Survival probabilities will be estimated
by Kaplan-Meier method and groups will be compared
using the log-rank test. A comparison of survival curves
will be only feasible after long term follow-up, currently
estimated as at least three years. Prognostic relevance of
tumor cell detection in blood and bone marrow will be
assessed using proportional hazards regression.BMC Surgery 2008, 8:6 http://www.biomedcentral.com/1471-2482/8/6
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The Cochran's Q test will be performed to correlate PCR
results with timing of blood collection.
Tumor cell detection rates in blood versus bone marrow
samples will be compared with the Mc Nemar's test.
Current status
At the current time point we have randomized 61 patients
in 2 different centers. The duration of the trial is expected
to be up to 3 more years. About 2–4 patients can be
enrolled per month. The interim analysis will be per-
formed during next year. Evaluation and reporting of the
clinical and laboratory results will be done within 3
month of the end of recruitment and closing of the data-
base.
Discussion
The primary objective of this study is to compare two sur-
gical resection techniques with regard to the extent of
intraoperative hematogenous tumor cell dissemination.
Tumor cell shedding into circulation during surgical
manipulation is a long debated issue. Previous studies
from our group demonstrated significantly enhanced
hematogenous tumor cell dissemination during resection
of primary tumor and liver metastases in patients with
colorectal cancer [7-9]. Furthermore, we could show a
prognostic impact of hematogenous tumor cell dissemi-
nation in patients with primary and metastatic colorectal
cancer [16]. Retrospective and prospective data from Liu
et al. indicated that the anterior approach technique pro-
vides a better survival compared to conventional resection
for patients with hepatocellular carcinoma [11,12]. It
remains unclear which aspect is mainly responsible for
the superior oncological outcome of patients with hepato-
cellular carcinoma undergoing the anterior approach
technique.
Therefore, we hypothesize that hematogenous tumor cell
dissemination may be reduced by using the anterior
approach technique compared to conventional liver resec-
tion. If this is true, tumor cell detection in blood and bone
marrow may serve as a surrogate marker for assessment of
oncological surgical procedures by detection of intraoper-
ative hematogenous tumor cell dissemination. Further-
more, detection of hematogenous tumor cell
dissemination could help to define a subgroup of patients
who benefit from additional therapy (e.g. antibody or
cytotoxic therapy) after extended surgical resection.
This hypothesis along with our above mentioned data
regarding tumor cell dissemination were the basis for the
conduction of this trial. This study is therefore a good
example for translation of molecular data into a clinical
trial.
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